Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2019-12-04
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn whether Tarceva (erlotinib
hydrochloride), when given in addition to whole brain radiation therapy, is better to treat
brain metastases in patients with Non-Small Cell Lung Cancer (NSCLC).